208 related articles for article (PubMed ID: 19717547)
1. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome.
Kiliç H; Zeytin HE; Korkmaz C; Mat C; Gül A; Coşan F; Dinç A; Simşek I; Süt N; Yazici H
Rheumatology (Oxford); 2009 Nov; 48(11):1388-91. PubMed ID: 19717547
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha treatment of Behçet's disease.
O'Duffy JD; Calamia K; Cohen S; Goronzy JJ; Herman D; Jorizzo J; Weyand C; Matteson E
J Rheumatol; 1998 Oct; 25(10):1938-44. PubMed ID: 9779847
[TBL] [Abstract][Full Text] [Related]
3. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
[TBL] [Abstract][Full Text] [Related]
4. A double-blind trial of depot corticosteroids in Behçet's syndrome.
Mat C; Yurdakul S; Uysal S; Gogus F; Ozyazgan Y; Uysal O; Fresko I; Yazici H
Rheumatology (Oxford); 2006 Mar; 45(3):348-52. PubMed ID: 16263779
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease.
Lee JH; Jung JY; Bang D
J Eur Acad Dermatol Venereol; 2008 May; 22(5):590-5. PubMed ID: 18093111
[TBL] [Abstract][Full Text] [Related]
6. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.
Melikoglu M; Fresko I; Mat C; Ozyazgan Y; Gogus F; Yurdakul S; Hamuryudan V; Yazici H
J Rheumatol; 2005 Jan; 32(1):98-105. PubMed ID: 15630733
[TBL] [Abstract][Full Text] [Related]
7. Topical granulocyte colony-stimulating factor for the treatment of oral and genital ulcers of patients with Behçet's disease.
Bacanli A; Yerebakan Dicle O; Parmaksizoglu B; Yilmaz E; Alpsoy E
J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):931-5. PubMed ID: 16922940
[TBL] [Abstract][Full Text] [Related]
8. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.
Deuter CM; Zierhut M; Möhle A; Vonthein R; Stöbiger N; Kötter I
Arthritis Rheum; 2010 Sep; 62(9):2796-805. PubMed ID: 20518075
[TBL] [Abstract][Full Text] [Related]
9. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
10. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
[TBL] [Abstract][Full Text] [Related]
11. An interim report on the effect of natural human interferon alpha (IFN-alpha) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1).
Babiuch L; Mian M; Kamińska E; Szymańska B; Georgiades JA
Arch Immunol Ther Exp (Warsz); 1993; 41(3-4):213-9. PubMed ID: 7907465
[TBL] [Abstract][Full Text] [Related]
12. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group.
Ship JA; Fox PC; Michalek JE; Cummins MJ; Richards AB
J Interferon Cytokine Res; 1999 Aug; 19(8):943-51. PubMed ID: 10476942
[TBL] [Abstract][Full Text] [Related]
13. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
14. Oral zinc sulfate in the treatment of Behcet's disease: a double blind cross-over study.
Sharquie KE; Najim RA; Al-Dori WS; Al-Hayani RK
J Dermatol; 2006 Aug; 33(8):541-6. PubMed ID: 16923135
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial.
Hamuryudan V; Hatemi G; Tascilar K; Sut N; Ozyazgan Y; Seyahi E; Mat C; Yurdakul S; Yazici H
Rheumatology (Oxford); 2010 Jan; 49(1):173-7. PubMed ID: 19995858
[TBL] [Abstract][Full Text] [Related]
16. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results.
Cummins MJ; Papas A; Kammer GM; Fox PC
Arthritis Rheum; 2003 Aug; 49(4):585-93. PubMed ID: 12910567
[TBL] [Abstract][Full Text] [Related]
17. [Behçet disease and exogenous interferon. A successful treatment study using recombinant alpha-A-IFN].
Stadler R; Bratzke B; Baumann I
Hautarzt; 1987 Feb; 38(2):97-100. PubMed ID: 3570783
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial.
Ramirez-Amador VA; Esquivel-Pedraza L; Ponce-de-Leon S; Reyes-Teran G; Gonzalez-Guevara M; Ponce-de-Leon S; Sierra-Madero JG
Clin Infect Dis; 1999 Apr; 28(4):892-4. PubMed ID: 10825055
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behçet's disease.
Köse O; Dinç A; Simşek I
Dermatology; 2009; 218(2):140-5. PubMed ID: 19060462
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
